At Taros Discovery, we offer a seamless, integrated approach to your drug discovery and development needs, providing the efficiency and reliability you can expect from a Europe-based CRO since 1999. Our expertise spans over medicinal chemistry and assay biology, helping clients accelerate their drug discovery projects with tailored solutions.

Taros' IDD services are primarily engaged for specific R&D programs where our expert teams contribute their expertise to strategic de-risking initiatives as well as higher-risk projects that require specialized scientific input.

Why Partner with Taros Discovery?

• Proven Track Record: Contributions to market-approved drugs like Tapentadol (Nucynta®) and Tramadol/Celecoxib co-crystal (Seglentis®) & >20 clinical candidates

• Comprehensive Services: From hit identification to preclinical candidates, including robust SAR studies, ADME/PK studies, and efficacy/Tox profiling for all modalities such as small molecules, PROTACs, Molecular Glues, solid-state chemistry, early formulation, and direct access to our clinical study center for pharmacology assessments and ex-vivo toxicology studies

• Cutting-Edge Capabilities: Access to proprietary libraries (European Lead Factory & DEL), high-throughput screening, and advanced technologies like CRISPR-based assays

• Tailored Solutions: Efficient, timely delivery of optimized compounds, with minimal DMTA cycles, with superior drug-like properties, driven by a collaborative approach.

Explore how Taros Discovery Can Accelerate Your Drug Discovery! Get in touch with us at info@taros.de or visits our website at https://www.tarosdiscovery.com/drug-discovery/.